Scott O Farnum1, Iuliia Makarenko2, Lynn Madden1,3, Alyona Mazhnaya2, Ruthanne Marcus4, Tanya Prokhorova2, Martha J Bojko4, Julia Rozanova4, Sergii Dvoriak5, Zahedsul Islam2, Frederick L Altice1,4,6. 1. APT Foundation, New Haven, CT, USA. 2. ICF Alliance for Public Health, Kyiv, Ukraine. 3. Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA. 4. Department of Medicine, Section of Infectious Diseases, Yale University School of Medicine, New Haven, CT, USA. 5. Ukrainian Institute on Public Health Policy, Kyiv, Ukraine. 6. Division of Epidemiology of Microbial Diseases, Yale University School of Public Health, New Haven, CT, USA.
Abstract
BACKGROUND AND AIMS: Ukraine's HIV epidemic remains concentrated among opioid-dependent people who inject drugs (PWID) where opioid agonist therapies (OAT) like methadone (MMT) and buprenorphine (BMT) maintenance treatments are the most cost-effective HIV prevention strategies, but remain under-scaled. This study aimed to measure the association between dose and type of OAT prescribed and treatment retention. DESIGN: Observational longitudinal cohort study. PARTICIPANTS AND SETTING: Patients (n = 15 290) prescribed OAT throughout Ukraine from 2004 through 2016. MEASUREMENTS: Data were analyzed using time-event strategies to estimate cumulative treatment retention, defined as time to OAT discontinuation. Cumulative retention proportions at 1, 12 and 36 months were assessed for outcomes. Cox regression with log-rank likelihood assessed independent predictors of treatment discontinuation. FINDINGS: The proportion prescribed high (MMT: > 85 mg; BMT: ≥ 16 mg), medium (MMT: > 40-85 mg; BMT: > 6-15 mg) and low (MMT: ≤ 40 mg; BMT: ≤ 6 mg) dosages was 25, 43 and 32%, respectively. Retention was significantly higher for BMT than MMT both at 12 (89 versus 75%) and 36 months (80 versus 56%). Although dosing levels for BMT did not influence retention, increasing dosages for MMT were significantly associated with higher retention rates at 1 (90, 96, 99%), 12 (59, 78, 91%) and 36 (34, 59, 79%) months, respectively. Independent predictors associated with 12-month OAT discontinuation were medium [adjusted hazard ratio (aHR) = 2.23; 95% confidence limit (CL) = 1.95-2.54] and low (aHR = 4.96; 95% CL = 4.37-5.63) OAT dosage relative to high dosage, male sex (aHR = 1.27; 95% CL = 1.14-1.41), MMT relative to BMT prescription (aHR = 1.57; 95% CL = 1.32-1.87) and receiving OAT in general (aHR = 1.22; 95% CL = 1.02-1.46) or tuberculosis (aHR = 1.43; 95% CL = 1.10-1.85) hospitals, relative to specialty addiction treatment and AIDS center settings. Lower dosages contributed more to dropout especially at 1 month (aHR 3.12; 95% CL = 2.21-4.41 and aHR 7.71; 95% CL = 5.51-10.79 for medium and low dosages, respectively). Younger age was significantly associated with OAT discontinuation only at 36 months (aHR = 1.08; 95% CI = 1.02-1.15). CONCLUSIONS: Higher dosages of opioid agonist therapies, especially for methadone maintenance treatment patients, appear to be associated with higher levels of treatment retention in Ukraine.
BACKGROUND AND AIMS: Ukraine's HIV epidemic remains concentrated among opioid-dependent people who inject drugs (PWID) where opioid agonist therapies (OAT) like methadone (MMT) and buprenorphine (BMT) maintenance treatments are the most cost-effective HIV prevention strategies, but remain under-scaled. This study aimed to measure the association between dose and type of OAT prescribed and treatment retention. DESIGN: Observational longitudinal cohort study. PARTICIPANTS AND SETTING: Patients (n = 15 290) prescribed OAT throughout Ukraine from 2004 through 2016. MEASUREMENTS: Data were analyzed using time-event strategies to estimate cumulative treatment retention, defined as time to OAT discontinuation. Cumulative retention proportions at 1, 12 and 36 months were assessed for outcomes. Cox regression with log-rank likelihood assessed independent predictors of treatment discontinuation. FINDINGS: The proportion prescribed high (MMT: > 85 mg; BMT: ≥ 16 mg), medium (MMT: > 40-85 mg; BMT: > 6-15 mg) and low (MMT: ≤ 40 mg; BMT: ≤ 6 mg) dosages was 25, 43 and 32%, respectively. Retention was significantly higher for BMT than MMT both at 12 (89 versus 75%) and 36 months (80 versus 56%). Although dosing levels for BMT did not influence retention, increasing dosages for MMT were significantly associated with higher retention rates at 1 (90, 96, 99%), 12 (59, 78, 91%) and 36 (34, 59, 79%) months, respectively. Independent predictors associated with 12-month OAT discontinuation were medium [adjusted hazard ratio (aHR) = 2.23; 95% confidence limit (CL) = 1.95-2.54] and low (aHR = 4.96; 95% CL = 4.37-5.63) OAT dosage relative to high dosage, male sex (aHR = 1.27; 95% CL = 1.14-1.41), MMT relative to BMT prescription (aHR = 1.57; 95% CL = 1.32-1.87) and receiving OAT in general (aHR = 1.22; 95% CL = 1.02-1.46) or tuberculosis (aHR = 1.43; 95% CL = 1.10-1.85) hospitals, relative to specialty addiction treatment and AIDS center settings. Lower dosages contributed more to dropout especially at 1 month (aHR 3.12; 95% CL = 2.21-4.41 and aHR 7.71; 95% CL = 5.51-10.79 for medium and low dosages, respectively). Younger age was significantly associated with OAT discontinuation only at 36 months (aHR = 1.08; 95% CI = 1.02-1.15). CONCLUSIONS: Higher dosages of opioid agonist therapies, especially for methadone maintenance treatment patients, appear to be associated with higher levels of treatment retention in Ukraine.
Authors: Chethan Bachireddy; Michael C Soule; Jacob M Izenberg; Sergey Dvoryak; Konstantin Dumchev; Frederick L Altice Journal: Drug Alcohol Depend Date: 2013-09-27 Impact factor: 4.492
Authors: Frederick L Altice; Adeeba Kamarulzaman; Vincent V Soriano; Mauro Schechter; Gerald H Friedland Journal: Lancet Date: 2010-07-31 Impact factor: 79.321
Authors: Jun Ma; Yan-Ping Bao; Ru-Jia Wang; Meng-Fan Su; Mo-Xuan Liu; Jin-Qiao Li; Louisa Degenhardt; Michael Farrell; Frederic C Blow; Mark Ilgen; Jie Shi; Lin Lu Journal: Mol Psychiatry Date: 2018-06-22 Impact factor: 15.992
Authors: Frederick L Altice; Lyuba Azbel; Jack Stone; Ellen Brooks-Pollock; Pavlo Smyrnov; Sergii Dvoriak; Faye S Taxman; Nabila El-Bassel; Natasha K Martin; Robert Booth; Heino Stöver; Kate Dolan; Peter Vickerman Journal: Lancet Date: 2016-07-14 Impact factor: 79.321
Authors: Roman Ivasiy; Lynn M Madden; Scott O Farnum; Natalia Shumskaya; Samy J Galvez de Leon; Daniel J Bromberg; Ainura Kurmanalieva; Aibek Duishenaliev; Ruslan Tokubaev; Frederick L Altice Journal: Drug Alcohol Depend Rep Date: 2022-07-19
Authors: Tara Gomes; Daniel McCormack; Nikki Bozinoff; Mina Tadrous; Tony Antoniou; Charlotte Munro; Tonya Campbell; J Michael Paterson; Muhammad Mamdani; Beth Sproule Journal: Addiction Date: 2022-03-21 Impact factor: 7.256